Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Lenalidomide, Dexamethasone, and Zoledronic Acid vs Zoledronic Acid in Solitary Plasmacytoma of Bone
NCT02516423Phase 3Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2016
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ixazomib, lenalidomide and dexamethasone in Solitary plasmacytoma of bone (SPB) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Symptomatic Myeloma Progression Free-survival Rate at 18 months. Started Nov 2016; status: terminated.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
Solitary plasmacytoma of bone (SPB)
Beyond the preview
Go deeper on NCT02516423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516423.